Insight Molecular Diagnostics Inc.

Insight Molecular Diagnostics Inc.

1.43
EUR
-0.38
(-20.99%)
-1.28EPS

Important Dates

Insight Molecular Diagnostics Inc.'s next confirmed earnings release is scheduled for November 16, 2026.

Earnings Date11/16/2026

Share Statistics

As of June 30, 2026, Insight Molecular Diagnostics Inc. has 32.62M shares outstanding.

Shares Outstanding32.62M

Financial Position

As of June 30, 2026, Insight Molecular Diagnostics Inc. maintains a current ratio of 2.00, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -12.32, indicating conservative leverage, while an interest coverage ratio of -488.32 demonstrates limited ability to service its debt obligations.

Current Ratio2.00
Quick Ratio1.74
Debt / Equity-12.32
Debt / EBITDA-0.05
Interest Coverage-488.32

Financial Efficiency

EUR

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -123.46, reflecting losses generated across the asset base. The company generates approximately 26,219.75 in revenue per employee across its workforce of 55.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.92 indicates how many times Insight Molecular Diagnostics Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Assets (ROA)-123.46
Revenue Per Employee26,219.75
Employee Count55.75
Inventory Turnover1.92

Stock Price Statistics

EUR

As of the close on November 17, 2026, Insight Molecular Diagnostics Inc.'s stock has declined approximately 47.04% over the past 52 weeks. The 50-day moving average sits at 2.61, while the 200-day moving average is 2.67.

52-Week Price Change-47.04%
50-Day Moving Average2.61
200-Day Moving Average2.67

Income Statement

EUR

Over the twelve months ended June 30, 2026, Insight Molecular Diagnostics Inc. generated 1.46M in revenue and converted that into -43.20M in net income, yielding earnings per share of -1.28. EBITDA reached -41.89M, while operating income came in at -32.42M.

Revenue1.46M
Gross Profit706,367.10
Operating Income-32.42M
Pretax Income-43.20M
Net Income-43.20M
EBITDA-41.89M
EBIT-44.03M
Earnings Per Share (EPS)-1.28

Balance Sheet

EUR

As of June 30, 2026, Insight Molecular Diagnostics Inc. holds 15.54M in cash and equivalents against 2.30M in total debt, resulting in a net debt position of -15.54M. Total book value stands at -18.64M, with working capital of 8.98M providing operational flexibility.

Cash & Cash Equivalents15.54M
Total Debt2.30M
Net Debt-15.54M
Equity (Book Value)-18.64M
Book Value Per Share-0.57
Working Capital8.98M

Cash Flow

EUR

Insight Molecular Diagnostics Inc. produced -23.70M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -3.43M in capital expenditures, free cash flow totaled -27.13M - equivalent to -0.80 per share.

Operating Cash Flow-23.70M
Capital Expenditures-3.43M
Free Cash Flow-27.13M
FCF Per Share-0.80

Margins

Over the twelve months ended June 30, 2026, Insight Molecular Diagnostics Inc. posted a gross margin of 48.32, reflecting its pricing power and cost economics. The operating margin of -2,217.90 and net profit margin of -2,955.63 provide insight into operational efficiency.

Gross Margin48.32
Operating Margin-2,217.90
Pretax Margin-2,955.63
Profit Margin-2,955.63
EBITDA Margin-2,865.57

Stock Splits

Insight Molecular Diagnostics Inc.'s most recent stock split took place on July 25, 2023 with a 20:1 split ratio.

Last Split Date7/25/2023
Split Ratio20:1